-
公开(公告)号：US08492429B2
公开(公告)日：2013-07-23
申请号：US12516062
申请日：2007-11-27
申请人： James Douglas Griffin , Leigh Zawel
发明人： James Douglas Griffin , Leigh Zawel
CPC分类号： A61K31/553 , A61K31/427 , A61K31/437 , A61K31/704 , A61K31/7068 , A61K2300/00
摘要： The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.
摘要翻译： 本发明涉及治疗血液恶性肿瘤的方法，包括急性骨髓性白血病（AML），其包括抑制Smac蛋白与IAP（“IAP抑制剂”）和一种或多种药物活性剂的结合的化合物的组合; 包含所述组合的药物组合物; 以及包括所述组合的商业包装。 本发明还涉及IAP抑制剂与一种或多种药物活性剂组合用于制备治疗血液恶性肿瘤（包括AML）的药物的用途。
-
公开(公告)号：US20100056467A1
公开(公告)日：2010-03-04
申请号：US12516062
申请日：2007-11-27
申请人： James Douglas Griffin , Leigh Zawel
发明人： James Douglas Griffin , Leigh Zawel
IPC分类号： A61K31/70 , A61K31/553 , A61K31/35
CPC分类号： A61K31/553 , A61K31/427 , A61K31/437 , A61K31/704 , A61K31/7068 , A61K2300/00
摘要： The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.
摘要翻译： 本发明涉及治疗血液恶性肿瘤的方法，包括急性骨髓性白血病（AML），其包括抑制Smac蛋白与IAP（“IAP抑制剂”）和一种或多种药物活性剂的结合的化合物的组合; 包含所述组合的药物组合物; 以及包括所述组合的商业包装。 本发明还涉及IAP抑制剂与一种或多种药物活性剂组合用于制备治疗血液恶性肿瘤（包括AML）的药物的用途。
-
公开(公告)号：US09700565B2
公开(公告)日：2017-07-11
申请号：US14928223
申请日：2015-10-30
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
-
4.发明授权Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity 有权星形孢菌素衍生物作为FLT3受体酪氨酸激酶活性的抑制剂公开(公告)号：US07973031B2
公开(公告)日：2011-07-05
申请号：US10493786
申请日：2002-10-29
IPC分类号： A61P35/02 , A61K31/55 , A61K31/535 , C07D498/22 , C07D487/04 , C07D487/14 , C07D519/00
CPC分类号： A61K31/407 , A61K31/535 , A61K31/55 , A61K31/553
摘要： The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
摘要翻译： 本发明涉及星形孢菌素衍生物在制备用于治疗涉及失调的FLT3受体酪氨酸激酶活性的疾病的药物中的用途，特别是用于治疗和/或预防性治疗白血病和骨髓增生异常综合征，以及治疗方法 涉及失调的FLT3受体酪氨酸激酶活性的疾病。
-
公开(公告)号：US20170209458A9
公开(公告)日：2017-07-27
申请号：US14928223
申请日：2015-10-30
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
-
6.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 审中-公开治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20120329779A1
公开(公告)日：2012-12-27
申请号：US13606070
申请日：2012-09-07
IPC分类号： A61K31/553 , C07D498/18 , A61P35/02
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
7.发明申请公开(公告)号：US20090286770A1
公开(公告)日：2009-11-19
申请号：US11721094
申请日：2005-12-07
IPC分类号： A61K31/553 , C07D245/06 , A61P35/00
CPC分类号： A61K31/407 , A61K31/553
摘要： The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving ras or FGFR3 signalling pathways and l or c-fos transcription, especially for the curative and/or prophylactic treatment of myeloma or multiple Myeloma, and to a method of treating diseases involving ras or FGFR3 signalling pathways and/or c-fos transcription.
摘要翻译： 本发明涉及星形孢菌素衍生物用于制备用于治疗涉及ras或FGFR3信号传导途径和l或c-fos转录的疾病的药物的用途，特别是用于治疗和/或预防性治疗骨髓瘤或多发性骨髓瘤， 以及治疗涉及ras或FGFR3信号传导途径和/或c-fos转录的疾病的方法。
-
8.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 有权治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20160184319A1
公开(公告)日：2016-06-30
申请号：US14928223
申请日：2015-10-30
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
9.发明申请Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias 审中-公开治疗混合谱系白血病基因重排的急性淋巴细胞性白血病的方法公开(公告)号：US20140303146A1
公开(公告)日：2014-10-09
申请号：US14311834
申请日：2014-06-23
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
10.发明申请METHOD OF TREATING MIXED LINEAGE LEUKEMIA GENE-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIAS 审中-公开治疗混合型淋巴细胞白血病基因突变型急性淋巴细胞白血病的方法公开(公告)号：US20140057897A1
公开(公告)日：2014-02-27
申请号：US14068017
申请日：2013-10-31
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.
摘要翻译： 本发明涉及治疗具有混合谱系白血病（MLL重排ALL）的温血动物，特别是人的方法，包括向所述动物施用治疗有效量的星形孢菌素衍生物，特别是PKC412或其药学上可接受的盐 单独或与另外的治疗措施结合使用，例如本文定义的那些; 使用星孢菌素衍生物制备用于治疗MLL重排ALL的药物; 以及包含星形孢菌素衍生物的商业包装以及用于治疗MLL重新排列的ALL的说明书。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.015 秒)
